Consequently, the pharmacological inhibition of PPARα reduced ANGPTL4 expression, which is involved in adipose-tissue-induced β-oxidation, proliferation, and the invasion of breast cancer cells [396]. Here, ANGPTL4 is linked to breast cancer.